TNDM

Tandem Diabetes Care, Inc.

Healthcare · $1.3B market cap

Verdict

We can't put a fair value on TNDM right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-16.1% a year✗
Sales growth32.4% a year✓
Free cash flow growth-36.0% a year✗
Return on invested capital-18.2%✗

Follow TNDM

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Oct 27, 2026: no open-market purchases, 1 sale worth $33K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Sales

Other filings

Questions about TNDM

Are insiders buying TNDM?

Since Oct 27, 2026: no open-market purchases, 1 sale worth $33K and 1 other filing (stock awards, tax withholding and similar).

How can I check TNDM's value myself?

Use the free Sticker Price calculator, already filled with TNDM's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →

Similar stocks · Medical - Devices

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.

Medical - Devices

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Oct 29, 2026. How the Payback Price works